Trial Profile
First-in-human Dose Escalation study of CD3-CD123 in Patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2018
Price :
$35
*
At a glance
- Drugs CD3-CD123 bispecific antibodies-Sanofi (Primary)
- Indications Acute myeloid leukaemia; B-cell leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- 04 Jul 2018 New trial record
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.